KRENSAVAGE ASSET MANAGEMENT LLC
Q2 2026 Form 13-F
NEW YORK, NEW YORK
CIK 0001609251
· CRD 168976
· SEC-registered investment adviser
$263.2M Reported Value Total
KRENSAVAGE ASSET MANAGEMENT, LLC reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $300,227,111, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $393.8M gross asset value
Hedge Fund: $393.8M
Source: Form ADV filed 2026-03-25
Reported value
$263.2M
Quarter over quarter
+4.9%
Holdings
18
Top-10 concentration
89.4%
Key People
Form ADV owners & control persons
Michael Paul Krensavage
MANAGING MEMBER/CHIEF EXECUTIVE OFFICER
Paul Joseph Paolino
CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $263.2M |
| Positions | 18 |
| Change in reported value | +2.9% |
| New positions | 0 |
| Exited positions | 2 |
| Position turnover | 10.0% |
| Top-10 concentration | 89.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
18 | $263.2M |
|
Q1 2026 13F
Filed May 15, 2026
|
20 | $255.7M |
|
Q4 2025 13F
Filed Feb 18, 2026
|
18 | $283.1M |
|
Q3 2025 13F
Filed Nov 17, 2025
|
17 | $234.7M |
|
Q2 2025 13F
Filed Aug 15, 2025
|
15 | $188.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
14 | $180.9M |
|
Q4 2024 13F
Filed Feb 18, 2025
|
12 | $169.0M |
|
Q3 2024 13F
Filed Nov 15, 2024
|
13 | $178.5M |
|
Q2 2024 13F
Filed Aug 15, 2024
|
13 | $217.8M |
|
Q1 2024 13F
Filed May 15, 2024
|
12 | $225.5M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
12 | $281.9M |
|
Q3 2023 13F
Filed Nov 15, 2023
|
12 | $271.6M |
|
Q2 2023 13F
Filed Aug 11, 2023
|
12 | $315.6M |
|
Q1 2023 13F
Filed May 16, 2023
|
12 | $329.3M |
|
Q4 2022 13F
Filed Feb 15, 2023
|
12 | $323.6M |
|
Q3 2022 13F
Filed Nov 15, 2022
|
14 | $314.1M |
|
Q2 2022 13F
Filed Aug 16, 2022
|
14 | $302.5M |
|
Q1 2022 13F
Filed May 17, 2022
|
13 | $290.1M |
|
Q4 2021 13F
Filed Feb 15, 2022
|
10 | $288.3M |
|
Q3 2021 13F
Filed Nov 16, 2021
|
13 | $318.8M |
27 earlier quarters on file — choose one from the quarter menu above.
Top 18 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ENTA ENANTA PHARMACEUTICALS INC | $41.8M | 15.88% |
| 2 | JAZZ JAZZ PHARMACEUTICALS PLC | $40.4M | 15.36% |
| 3 | UTHR UNITED THERAPEUTICS CORP | $37.5M | 14.26% |
| 4 | BMRN BIOMARIN PHARMACEUTICAL INC | $30.0M | 11.41% |
| 5 | EXEL EXELIXIS INC | $20.2M | 7.66% |
| 6 | ABT ABBOTT LABORATORIES | $18.1M | 6.89% |
| 7 | SNY SANOFI-ADR | $13.8M | 5.25% |
| 8 | SUPN SUPERNUS PHARMACEUTICALS INC | $13.1M | 4.96% |
| 9 | RARE ULTRAGENYX PHARMACEUTICAL IN | $13.1M | 4.96% |
| 10 | VNDA VANDA PHARMACEUTICALS INC | $7.2M | 2.74% |
| 11 | BNTX BIONTECH SE-ADR | $5.5M | 2.1% |
| 12 | GSK GSK PLC-SPON ADR | $5.1M | 1.93% |
| 13 | BIIB BIOGEN INC | $4.3M | 1.64% |
| 14 | REGN REGENERON PHARMACEUTICALS | $3.7M | 1.42% |
| 15 | EMBC EMBECTA CORP | $3.7M | 1.41% |
| 16 | ARDX ARDELYX INC | $2.7M | 1.04% |
| 17 | INMD INMODE LTD | $1.8M | 0.67% |
| 18 | EOLS EVOLUS INC | $1.1M | 0.42% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.